For a patient with hypertension or type 2 diabetes standing at a pharmacy counter, the moment of truth is rarely the diagnosis. It is the receipt. A generic that should cost twelve dollars at one pharmacy can ring up at ninety at another, and the prescribing physician, three hours and a dozen patients removed from the encounter, almost never knows. eNavvi, a small healthtech company led by co-founder and CEO Simon Chang, is betting that putting the cash price in front of the clinician at the point of prescribing, for free, is enough of a wedge to pull prescribers off the default workflows baked into their electronic medical records [Crunchbase].
The patient population in question is broad: anyone in the United States filling a chronic medication where the cash price, often through networks like the Mark Cuban Cost Plus Drug Company, undercuts what their insurance would adjudicate after deductibles and coinsurance. eNavvi's product is a web-based prescribing tool that surfaces real-time cash prices across a pharmacy network, flags prior authorization requirements and step therapy protocols, and routes electronic prescriptions to pharmacies nationwide [eNavvi]. The company describes it as designed by physicians for physicians, and lists Cost Plus Drugs among its pharmacy network partners [eNavvi].
The bet
eNavvi's wedge is price transparency at the moment of decision, delivered outside the EMR. Most prescribers today work inside Epic, Cerner, athenahealth, or eClinicalWorks, where formulary data reflects what a given insurance plan will cover, not what the patient would pay in cash at a competing pharmacy down the street. eNavvi positions itself as a complement to that workflow, free to clinicians, with revenue implied to come from the pharmacy network and compounding partners rather than from physician seats [Wefunder]. In January 2026, the company announced a partnership with SandsRx to expand sterile and non-sterile compounding access for dermatology, weight management, and hormone replacement therapy prescribers, three categories where cash-pay and compounded products dominate and insurance adjudication is often absent [PRNewswire, 2026].
That compounding angle matters. As eNavvi itself notes, compounded topicals are typically not adjudicated by pharmacy benefit managers because they lack FDA approval as finished products, which makes transparent cash pricing the only meaningful signal a prescriber has [eNavvi]. GLP-1 weight management drugs, hormone therapy, and dermatology compounds are among the fastest-growing cash-pay categories in American outpatient medicine, and they sit largely outside the standard ePrescribing price-check flow.
Standard of care today
For a primary care physician writing a prescription for metformin, lisinopril, sertraline, or atorvastatin, the standard of care is to send the script through the EMR's integrated ePrescribing module, typically Surescripts-routed, with a real-time benefit check that returns the patient's estimated copay under their pharmacy benefit. That check is useful when it works, but it does not compare against cash-pay options at independent pharmacies, mail-order discounters, or direct-to-consumer pharmacies like Cost Plus Drugs. Patients who want a better price typically have to discover GoodRx or Cost Plus on their own, then call the office to request the prescription be re-sent to a different pharmacy. eNavvi is trying to collapse that loop into the original prescribing decision.
Why it could matter
The macro picture favors price transparency tools. CMS hospital and payer transparency rules, the federal No Surprises Act, and growing state-level pharmacy pricing legislation have all pushed cost data closer to the point of care. Direct-to-consumer pharmacy economics, popularized by Cost Plus Drugs, have demonstrated that a meaningful share of common generics can be dispensed at a fraction of insurance-adjudicated prices. If eNavvi can become the default cash-price overlay for prescribers in high-cash-pay specialties, the compounding and weight-management partnerships suggest a plausible revenue path that does not depend on charging clinicians.
Team and traction
Simon Chang, DO, is co-founder and CEO [Crunchbase]. The team listed on LinkedIn includes Reddy Pathakota, MD, MBA; Alex Prevallet, DO; Sergio Manuel Pérez Mayo; Sebastian Fleck; Kunal Joshi, MD, MBA; and Yair Saperstein [LinkedIn]. The clinician density on the cap table is unusual for a software company at this stage and is consistent with the product's framing as built by prescribers who have lived the workflow problem.
Funding has been modest and largely community-sourced. eNavvi reports approximately $250,000 secured through direct investments as of April 2025 [eNavvi, April 2025], with an earlier $80,000 angel round led through WeFunder [CBInsights]. The company has also signaled a redesigned experience with full ePrescribing and EPCS (Electronic Prescriptions for Controlled Substances) capabilities arriving in May 2026 [eNavvi].
| Round | Date | Amount | Lead |
|---|---|---|---|
| Angel | Undisclosed | $80,000 | WeFunder |
| Seed | April 2025 | $250,000 | Undisclosed |
The honest counterfactual
What skeptics will ask: can a free, standalone prescribing tool win behavior change against EMR-integrated workflows that already include real-time benefit checks and Surescripts routing? Switching costs for prescribers are real, and the broader ePrescribing market is dominated by incumbents whose distribution runs through hospital IT contracts, not individual physician adoption. The bull answer, supported by eNavvi's own positioning, is that the company is not trying to replace Epic. It is targeting the cash-pay and compounding categories where EMR formulary data is least useful and where independent and direct-to-consumer prescribers, telehealth clinicians, and specialty practices are already operating outside hospital IT. The SandsRx partnership in dermatology, weight management, and HRT [PRNewswire, 2026] is consistent with that wedge.
Regulatory context is worth naming. ePrescribing of controlled substances is governed by DEA EPCS requirements, and any platform routing scripts nationwide must maintain Surescripts certification and state-by-state compliance. eNavvi's planned May 2026 EPCS rollout [eNavvi] will be a meaningful technical and regulatory milestone, and the readiness of that release is the single most important near-term signal for whether the platform graduates from a price-comparison overlay into a full prescribing tool.
What to watch
The next twelve months will turn on three things: whether the May 2026 EPCS-capable release ships on time and clears certification, whether the SandsRx partnership produces measurable prescriber adoption in cash-pay specialties, and whether eNavvi can convert its physician-investor base into a clinician user base large enough to attract a priced institutional round. For now, the company is small, the funding is early, and the bet is narrow. But the patient standing at the pharmacy counter, holding a receipt for a drug they cannot afford, is a problem the existing prescribing stack has not solved. That is reason enough to keep watching.